AUTHORS
Nikolaos Spyrou, MD, MSc, Pavlina Chrysafi, MD2, Chi-Joan How, MD3, Rebecca Zon, MD4, Damon E Houghton, MD, MS5, Atefeh Ghorbanzadeh6, Sai Alladi7, Vrushali Pachpande, MD, MS8, Sai Valisekka, MBBS9, Balkrishna Jahagirdar, MBBS10, Sargam Kapoor, MBBS11, Andrew Peseski, DO12, Ruchi Desai, MD13, Guoliang Zheng14, Shreyash Dalmia, MD15, Vinai Bhagirath, MD, MSc, FRCPC16, Alejandro Godoy17, Alessandro Vannucchi, MD18, Valerio De Stefano19, Silvia Betti20, Elena Rossi, MD, PhD21, Jonathan Berry, MD22, Margherita Maffioli23, Gabriela Soriano Hobbs, MD24, Alla Keyzner, MD25, Amica K. Ko, MD, MSc26, Lisa Baumann Kreuziger, MD, MS27, Rushad Patell, MD28, Joan Denise Beckman, Lois, RichardKingAssistantProfessorandMcKnightLand-GrantProfessor29, Mandy N. Lauw, MD, PhD30, Douglas Tremblay, MD31
AFFILIATIONS
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Brigham & Women's Hospital, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Jacksonville, Florida, United States
8 University of Minnesota, Minneapolis, Minnesota, United States
9 University of Minnesota, Minneapolis, Minnesota, United States
10 University of Minnesota, Minneapolis, Minnesota, United States
11 Duke University, Durham, North Carolina, United States
12 Duke University, Durham, North Carolina, United States
13 Virginia Commonwealth University, Richmond, Virginia, United States
14 Virginia Commonwealth University, Richmond, Virginia, United States
15 McMaster University, Hamilton, Ontario, Canada
16 McMaster University, Hamilton, Ontario, Canada
17 McMaster University, Hamilton, Ontario, Canada
18 University of Florence, Florence, Italy
19 Catholic University, Rome, Italy
20 Catholic University, Rome, Italy
21 Catholic University, Rome, Italy
22 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
23 Hematology Unit, ASST Sette Laghi, Varese, Italy
24 Massachusetts General Brigham Cancer Institute, Boston, Massachusetts, United States
25 Icahn School of Medicine at Mount Sinai, New York, New York, United States
26 Erasmus University Medical Center, Rotterdam, Netherlands
27 Versiti, Milwaukee, Wisconsin, United States
28 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
29 University of Minnesota, Minneapolis, Minnesota, United States
30 Erasmus University Medical Center, Rotterdam, Netherlands
31 Icahn School of Medicine at Mount Sinai, New York, New York, United States
ABSTRACT
Background
Splanchnic vein thrombosis (SVT), encompassing thrombosis in the portal vein, mesenteric vein, splenic vein or hepatic veins, is a serious complication of myeloproliferative neoplasms (MPNs). Patients with MPN-associated SVT (MPN-SVT) have a persistent prothrombotic state and risk for portal hypertension, variceal bleeding, and hepatic decompensation. Allogeneic stem cell transplantation (SCT) remains the only curative therapy for MPN and is indicated in higher-risk myelofibrosis (MF) and accelerated/blast phase MPN. We evaluated the characteristics and outcomes of patients with MPN-SVT undergoing SCT.
Methods
We conducted a retrospective analysis of the GASTRO-MPN international registry. Adult patients (≥18 years) with MPN-SVT who subsequently underwent allogeneic SCT and with sufficient follow-up data were included. Patient characteristics were summarized descriptively. Overall survival (OS), cumulative incidence of recurrent thrombosis (composite of recurrent/progressive SVT, or extra-splanchnic recurrent venous or arterial thromboembolism), and cumulative incidence of any clinically relevant bleeding (non-major or major bleeding as defined by International Society on Thrombosis and Haemostasis) were estimated from the date of SCT using Kaplan-Meier and cumulative incidence methods and reported at 100 days, 1, 3, and 5 years post-SCT.
Results
Of 914 patients in the GASTRO-MPN registry, 42 underwent SCT after diagnosis of their MPN-SVT. The median time from SVT diagnosis to SCT was 18.1 months (interquartile range 4.2 to 101.5 months). The median age was 51.5 years (range 31-74) and 22 patients (52.4%) were male.
SVT occurred in multiple veins in 26 patients (61.9%), with isolated portal vein thrombosis in 8 (19.0%), splenic vein in 6 (14.3%), and hepatic vein thrombosis in 1 patient (2.4%), and missing site for 1 patient (2.4%). One patient (2.4%) had undergone transjugular intrahepatic portosystemic shunt (TIPS) placement prior to SCT.
At the time of SCT, the underlying MPN was primary myelofibrosis (MF) in 18 patients (42.9%), secondary MF in 17 (40.5%), blast phase in 5 (11.9%), and polycythemia vera in 2 (4.8%). Most patients had a MPN driver mutation (78.6% JAK2V617F, 7.1% CALR, 4.8% MPL, 9.5% triple-negative disease). Twelve patients (28.6%) harbored secondary mutations (19% ASXL1, 7.1% TET2, 4.8% DNMT3A, 4.8% KRAS, 4.8% NRAS, 2.4% EZH2, 2.4% IDH1, 2.4% SF3B1; mutation frequencies are not mutually exclusive) at MPN diagnosis.
Within the 30 days around SCT (30 days pre- and 30 days post-SCT), 27 patients (64.3%) were receiving therapeutic anticoagulation, most commonly LMWH (26.2%), DOACs (19.0%), or warfarin (16.7%), and 24 patients (57.1%) were receiving cytoreductive therapy, predominantly ruxolitinib (42.9%).
The 100-day, 1-year, 3-year, and 5-year OS rates were 88.1%, 75.8%, 64.8%, and 61.4%, respectively (16 deaths; median OS not reached within the observation window). Cumulative incidence of recurrent thrombosis post-SCT was 7.8% at 100 days, 14.4% at 1 year, 25.8% at 3 years, and 30.7% at 5 years (10 events). Thrombotic events included SVT recurrence/progression in 4 (9.5%), pulmonary embolism in 4 patients (9.5%) and deep vein thrombosis in 2 (4.8%).
The cumulative incidence of clinically relevant bleeding post-SCT was 12.6% at 100 days, and plateaued at 15.2% at 1, 3, and 5 years (6 events). Gastrointestinal bleeding was the most common site, accounting for 3 of 6 events (50.0%), with additional bleeding involving intracranial, intrathoracic, and other sites. Most of the bleeding events occurred during thrombocytopenia (four during grade 3-4 thrombocytopenia, one during grade 1 thrombocytopenia, one with normal platelets).
Conclusions
In this first reported cohort of patients with MPN-SVT undergoing allogeneic SCT, transplant outcomes are comparable to broader MPN transplant populations, with a 5-year OS of 61.4%. Recurrent thrombosis accumulated steadily, affecting approximately 1 in 4 patients by 3 years, while clinically relevant bleeding events occurred early with an incidence of 15.2%. Non-relapse mortality, cause of death, and the incidence of veno-occlusive disease or other hepatotoxicity were not collected in the registry and could therefore not be analyzed. These findings benchmark survival and vascular outcomes for patients with MPN-SVT undergoing SCT and suggest SCT feasibility in select patient groups.
DISCLOSURES
Nikolaos Spyrou, MD, MSc: No relevant conflicts of interest to declare.